NASDAQ:KTRA Kintara Therapeutics (KTRA) Stock Price, News & Analysis $0.17 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.17▼$0.1850-Day Range$0.17▼$0.3052-Week Range$0.08▼$4.92Volume1.54 million shsAverage Volume10.96 million shsMarket Capitalization$9.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Kintara Therapeutics alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Kintara Therapeutics Stock (NASDAQ:KTRA)Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.Read More KTRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KTRA Stock News HeadlinesAugust 19, 2024 | prnewswire.comTuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerJuly 8, 2024 | prnewswire.comTuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint InhibitorSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...July 1, 2024 | prnewswire.comKintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term MilestonesJune 3, 2024 | prnewswire.comTuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)May 29, 2024 | finance.yahoo.comKintara Therapeutics, Inc. (KTRA)May 14, 2024 | prnewswire.comKintara Therapeutics Announces Fiscal 2024 Third Quarter Financial ResultsMay 3, 2024 | nasdaq.comKintara Therapeutics, Inc. Common Stock (KTRA)September 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...April 11, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, CTLT, SCX, KTRAApril 10, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, KTRAApril 9, 2024 | prnewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRAApril 5, 2024 | businesswire.comKINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRAApril 5, 2024 | finance.yahoo.comAPhA and CDC select Community of Practice Teams to advance health equity and prevent heart disease and strokeApril 3, 2024 | markets.businessinsider.comCrude Oil Moves Higher; ISM Services PMI Falls In MarchApril 3, 2024 | msn.comWhy Kintara Therapeutics Shares Are Gaining TodayApril 3, 2024 | stockhouse.comKTRA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kintara Therapeutics, Inc. Is Fair to ShareholdersApril 3, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURASee More Headlines Receive KTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kintara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today9/07/2024Next Earnings (Estimated)9/16/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KTRA CUSIPN/A CIK1498382 Webwww.kintara.com Phone(858) 350-4364Fax604-608-5685Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,650,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-257.25% Debt Debt-to-Equity RatioN/A Current Ratio5.04 Quick Ratio5.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($5.86) per share Price / Book-0.03Miscellaneous Outstanding Shares55,305,000Free Float55,194,000Market Cap$9.62 million OptionableNot Optionable Beta0.81 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Robert E. Hoffman B.B.A. (Age 58)CPA, President, CEO, CFO & Chairman of the Board Comp: $767.98kMr. Jeffrey A. Bacha B.Sc. (Age 56)M.B.A., Founder Mr. Greg A. JohnsonActing Head of OperationsKey CompetitorsMillendo TherapeuticsNASDAQ:MLNDLantern PharmaNASDAQ:LTRNCleneNASDAQ:CLNNReviva PharmaceuticalsNASDAQ:RVPHImmuneeringNASDAQ:IMRXView All Competitors KTRA Stock Analysis - Frequently Asked Questions How have KTRA shares performed this year? Kintara Therapeutics' stock was trading at $0.1696 at the beginning of the year. Since then, KTRA stock has increased by 2.5% and is now trading at $0.1739. View the best growth stocks for 2024 here. How were Kintara Therapeutics' earnings last quarter? Kintara Therapeutics, Inc. (NASDAQ:KTRA) posted its quarterly earnings data on Monday, November, 15th. The company reported ($8.50) EPS for the quarter, missing the consensus estimate of ($7.00) by $1.50. When did Kintara Therapeutics' stock split? Shares of Kintara Therapeutics reverse split before market open on Monday, November 14th 2022. The 1-50 reverse split was announced on Monday, November 14th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 14th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Kintara Therapeutics? Shares of KTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Kintara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kintara Therapeutics investors own include Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Fortress Biotech (FBIO), Immunic (IMUX) and Miragen Therapeutics (MGEN). This page (NASDAQ:KTRA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredHere’s A Painful Truth and 100% Fact About The Stocks You’re HoldingCharles Payne here, and I want to let you in on an uncomfortable truth that long term investors and retirees n...Unstoppable Prosperity | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kintara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kintara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KTRA Stock Alerts